Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Tumor Inhibition by DepoVax-Based Cancer Vaccine Is Accompanied by Reduced Regulatory/Suppressor Cell Proliferation and Tumor Infiltration.

Karkada M, Quinton T, Blackman R, Mansour M.

ISRN Oncol. 2013;2013:753427. doi: 10.1155/2013/753427. Epub 2013 Mar 7.

2.

A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses.

Karkada M, Weir GM, Quinton T, Sammatur L, MacDonald LD, Grant A, Liwski R, Juskevicius R, Sinnathamby G, Philip R, Mansour M.

J Immunother. 2010 Apr;33(3):250-61. doi: 10.1097/CJI.0b013e3181c1f1e9.

PMID:
20445345
3.
4.

Therapeutic vaccines and cancer: focus on DPX-0907.

Karkada M, Berinstein NL, Mansour M.

Biologics. 2014 Feb 10;8:27-38. doi: 10.2147/BTT.S55196. eCollection 2014. Review.

5.

Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response.

Weir GM, Hrytsenko O, Stanford MM, Berinstein NL, Karkada M, Liwski RS, Mansour M.

Oncoimmunology. 2014 Nov 14;3(8):e953407. eCollection 2014.

6.

First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients.

Berinstein NL, Karkada M, Morse MA, Nemunaitis JJ, Chatta G, Kaufman H, Odunsi K, Nigam R, Sammatur L, MacDonald LD, Weir GM, Stanford MM, Mansour M.

J Transl Med. 2012 Aug 3;10:156. doi: 10.1186/1479-5876-10-156.

7.

Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication.

Draghiciu O, Nijman HW, Hoogeboom BN, Meijerhof T, Daemen T.

Oncoimmunology. 2015 Jan 7;4(3):e989764. eCollection 2015 Mar.

8.

Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine.

Chang EY, Chen CH, Ji H, Wang TL, Hung K, Lee BP, Huang AY, Kurman RJ, Pardoll DM, Wu T.

Int J Cancer. 2000 Jun 1;86(5):725-30.

9.

Histone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination.

Lee SY, Huang Z, Kang TH, Soong RS, Knoff J, Axenfeld E, Wang C, Alvarez RD, Chen CS, Hung CF, Wu TC.

J Mol Med (Berl). 2013 Oct;91(10):1221-31. doi: 10.1007/s00109-013-1054-9. Epub 2013 May 29.

10.

Vasoactive intestinal peptide induces CD14+HLA-DR‑/low myeloid-derived suppressor cells in gastric cancer.

Li G, Wu K, Tao K, Lu X, Ma J, Mao Z, Li H, Shi L, Li J, Niu Y, Xiang F, Wang G.

Mol Med Rep. 2015 Jul;12(1):760-8. doi: 10.3892/mmr.2015.3374. Epub 2015 Feb 18.

PMID:
25695487
11.

Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects.

Peng S, Trimble C, Alvarez RD, Huh WK, Lin Z, Monie A, Hung CF, Wu TC.

Gene Ther. 2008 Aug;15(16):1156-66. doi: 10.1038/gt.2008.53. Epub 2008 Apr 10.

12.

Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination.

Draghiciu O, Walczak M, Hoogeboom BN, Franken KL, Melief KJ, Nijman HW, Daemen T.

Int J Cancer. 2014 Feb 15;134(4):859-72. doi: 10.1002/ijc.28418. Epub 2013 Sep 4.

14.
15.

Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients.

Berinstein NL, Karkada M, Oza AM, Odunsi K, Villella JA, Nemunaitis JJ, Morse MA, Pejovic T, Bentley J, Buyse M, Nigam R, Weir GM, MacDonald LD, Quinton T, Rajagopalan R, Sharp K, Penwell A, Sammatur L, Burzykowski T, Stanford MM, Mansour M.

Oncoimmunology. 2015 May 7;4(8):e1026529. eCollection 2015 Aug.

16.

Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.

Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Löwik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der Burg SH.

Clin Cancer Res. 2008 Jan 1;14(1):178-87. doi: 10.1158/1078-0432.CCR-07-1880.

17.

Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts.

Maenhout SK, Van Lint S, Emeagi PU, Thielemans K, Aerts JL.

Int J Cancer. 2014 Mar 1;134(5):1077-90. doi: 10.1002/ijc.28449. Epub 2013 Sep 23.

18.

Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice.

Peng S, Trimble C, He L, Tsai YC, Lin CT, Boyd DA, Pardoll D, Hung CF, Wu TC.

Gene Ther. 2006 Jan;13(1):67-77.

19.

Enhancement of DNA vaccine potency by sandwiching antigen-coding gene between secondary lymphoid tissue chemokine (SLC) and IgG Fc fragment genes.

Liu R, Zhou C, Wang D, Ma W, Lin C, Wang Y, Liang X, Li J, Guo S, Wang Y, Zhang Y, Zhang S.

Cancer Biol Ther. 2006 Apr;5(4):427-34. Epub 2006 Apr 20.

PMID:
16575207
20.

Supplemental Content

Support Center